S-3 - Transcode Therapeutics, Inc. (0001829635) (Filer)

8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

10-Q - Transcode Therapeutics, Inc. (0001829635) (Filer)

SCHEDULE 13G/A - Transcode Therapeutics, Inc. (0001829635) (Subject)

SCHEDULE 13D/A - Transcode Therapeutics, Inc. (0001829635) (Subject)

DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)

8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)

8-K/A - Transcode Therapeutics, Inc. (0001829635) (Filer)

SCHEDULE 13D - Transcode Therapeutics, Inc. (0001829635) (Subject)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4/A - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

BOSTON, Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate TransCode's lead therapeutic candidate TTX-MC138 as part of the Quantum Leap PRE-I-SPY clinical trial platform. The PRE-I-SPY program will incorporate TTX-MC138 in a Phase 2a dose-expansion clinical trial enrolling up to 45 patients with colorectal cancer who have completed standard curative-intent therapy and are ctDNA positive. The Phase 2a portion of the trial is planned to begin in the fir

Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence BOSTON, Nov. 17, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy, announced today the appointment of Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer. Dr. Janicot brings more than 35 years of experience in pharmaceutical research, preclinical, and early clinical drug development across oncology and other therapeutic areas. He will serve initially on a part-time basis. 

Safety primary endpoint achievedMedian treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trialRECIST data with apparent stable disease lasting over 4 months in 44% of patients (7 out of 16)Safety and durability profile consistent with known mechanism of actionEarly signals support advancement to a Phase 2a clinical trial with established treatment doseBOSTON, Oct. 14, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announces completion of Phase 1a clinical trial with TTX-MC138, an investigational inhibitor of microRNA-10b, or miR-10b. By meeting its primary safety endpoint and defining a recommended Phase 2 dose, TTX-MC138 is moving fo

TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life SciencesConcurrent equity investment of $25 Million from CK Life Sciences into TransCodeTransCode expands its microRNA-based pipeline with Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanomaPhilippe Calais, PharmD, PhD, becomes Chief Executive Officer and remains Chairman of the Board. Tom Fitzgerald, MBA, remains Chief Financial Officer. Elizabeth Czerepak, MBA, appointed as a new independent Board Member and Chairperson of the Audit CommitteeBOSTON and SAN DIEGO, Oct. 8, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) (

RNA pioneer and biotechnology innovator joins TransCode Therapeutics Science Advisory Board to advance RNA oncologyDr. Zamore co-founded Alnylam Pharmaceuticals in 2002, which developed and commercialized the first FDA-approved RNAi drugBOSTON, May 28, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical-stage oncology company developing RNA-targeted therapeutics for the treatment of cancer, today announced the appointment of Phillip D. Zamore, Ph.D., to its Scientific Advisory Board. Dr. Zamore is a prominent biotechnology innovator known for his pioneering work in RNA interference (RNAi). Together with world-renowned scientists, including  Nobel Laureate, Dr Phillip

15 patients treated across four escalating dose levels of TTX-MC138No significant safety or dose limiting toxicities reported10 patients remain on study with no evidence of disease progressionPD analysis at 24 hours post-dosing provides evidence of miR-10b target engagementBOSTON, May 8, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the third patient in Cohort 4 of its Phase 1a clinical trial has received their initial dose of TTX-MC138. All cohorts have enrolled at least three patients who have been dosed with TTX-MC138 at least once. The Safety Review Commi

BOSTON, May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved an effective time at 12:01 a.m. Eastern Standard Time May 15, 2025, for its 1-for-28 reverse stock split. TransCode's common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on May 15, 2025, under the current trading symbol, "RNAZ." The reverse stock split was approved by TransCode's stockholders and Board of Directors on May 2, 2025, and is intended to increase the per share trading price of

Split designed to achieve compliance with Nasdaq minimum bid price requirements BOSTON, May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-28 reverse stock split. The reverse stock split was approved by TransCode's stockholders on May 2, 2025, and is intended to increase the per share trading price of the Company's common stock to enable the Company to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

A total of 13 patients treated with four escalating doses of TTX-MC138No significant safety or dose limiting toxicities reportedTwo patients have so far maintained stable disease on treatment for at least seven monthsPD analysis at 24 hours post-dosing provides evidence of miR-10b target engagementBOSTON, May 1, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced further progress in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer. TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA wide

BOSTON, April 21, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced its Special Meeting scheduled for and convened on April 21, 2025, (the "Special Meeting") has been adjourned until May 2, 2025, at 9:30 a.m. Eastern time (the "Adjourned Special Meeting") for the purpose of soliciting additional votes with respect to the proposals outlined below and described in the Company's definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission (the "SEC") on April 11, 2025 (the "Special Meeting Proxy Stat

Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence BOSTON, Nov. 17, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy, announced today the appointment of Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer. Dr. Janicot brings more than 35 years of experience in pharmaceutical research, preclinical, and early clinical drug development across oncology and other therapeutic areas. He will serve initially on a part-time basis. 

RNA pioneer and biotechnology innovator joins TransCode Therapeutics Science Advisory Board to advance RNA oncologyDr. Zamore co-founded Alnylam Pharmaceuticals in 2002, which developed and commercialized the first FDA-approved RNAi drugBOSTON, May 28, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical-stage oncology company developing RNA-targeted therapeutics for the treatment of cancer, today announced the appointment of Phillip D. Zamore, Ph.D., to its Scientific Advisory Board. Dr. Zamore is a prominent biotechnology innovator known for his pioneering work in RNA interference (RNAi). Together with world-renowned scientists, including  Nobel Laureate, Dr Phillip

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that Daniel Vlock, M.D., has been appointed as the company's Chief Medical Officer. Dr. Vlock is a medical oncologist with over 25 years of industry experience and 15 years in academia, including renowned institutions Yale University, University of Pittsburgh, and Harvard University. Dr. Vlock has successfully supported start-up, emerging, and established companies with diverse product portfolios.  He has played key roles in managing pre-IND, phase I, II and III clinical trials, and post–approv

BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the third quarter ended September 30, 2022, and recent business progress. "We continued to advance our therapeutic programs during the third quarter," said Michael Dudley, co-founder, president and CEO of TransCode. "We remain on track to achieve our planned milestones for 2H of 2022 which include submission of an exploratory Investigational New Drug Application (eIND) this year for our planned Phase 0 clinical trial in up to 12 cancer patients with advanced solid tumors. We

BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the appointment of Frank J. Slack, PhD, to its advisory board. "Dr. Slack is one of the most preeminent scientists in the field of small noncoding RNA," commented Zdravka Medarova, PhD, Co-Founder and CTO of TransCode. "Having pioneered pivotal studies proving that microRNAs drive oncogenesis and represent critical targets for the treatment of cancer, his guidance will prove indispensable as TransCode enters the clinical phase of development." Dr. Slack is the Shields Warren Mallinckrodt Profe

TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life SciencesConcurrent equity investment of $25 Million from CK Life Sciences into TransCodeTransCode expands its microRNA-based pipeline with Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanomaPhilippe Calais, PharmD, PhD, becomes Chief Executive Officer and remains Chairman of the Board. Tom Fitzgerald, MBA, remains Chief Financial Officer. Elizabeth Czerepak, MBA, appointed as a new independent Board Member and Chairperson of the Audit CommitteeBOSTON and SAN DIEGO, Oct. 8, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) (

BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce its execution of an option agreement giving TransCode the right to negotiate an exclusive, worldwide, royalty-bearing license related to a radiotheranostic technology disclosed in patent application PCT/US2021/057912 entitled THERAPEUTIC, RADIOLABLED NANOPARTICLES AND METHODS OF USE THEREOF. Invented by TransCode Co-Founder and CTO, Dr. Zdravka Medarova, and her colleagues at Massachusetts General Hospital, the technology represents another potential advancement in the diagnosis and treatment of cancer.

SC 13G/A - Transcode Therapeutics, Inc. (0001829635) (Subject)

SC 13G - Transcode Therapeutics, Inc. (0001829635) (Subject)

SC 13D - Transcode Therapeutics, Inc. (0001829635) (Subject)

SC 13G/A - Transcode Therapeutics, Inc. (0001829635) (Subject)

SC 13G/A - Transcode Therapeutics, Inc. (0001829635) (Subject)

SC 13G/A - Transcode Therapeutics, Inc. (0001829635) (Subject)

SC 13G - Transcode Therapeutics, Inc. (0001829635) (Subject)

SC 13D/A - Transcode Therapeutics, Inc. (0001829635) (Subject)

SC 13G - Transcode Therapeutics, Inc. (0001829635) (Subject)

SC 13D/A - Transcode Therapeutics, Inc. (0001829635) (Subject)